Validated high-conviction buyer — this insider’s opportunistic purchases fall in a cohort whose buys have historically preceded above-benchmark moves. How we measure this ↗
Director John Henneman purchases 5,000 shares at market; stock down from highs amid company's ongoing losses.
John Henneman, a director of Orthofix Medical, purchased 5,000 shares on the open market, increasing his stake by a meaningful portion. The timing is noteworthy: the stock is trading well below its recent highs, having declined over the past quarter, which is a classic setup for insider conviction purchases. However, this conviction is tempered by the company's financial reality — Orthofix is currently unprofitable with negative earnings in both the latest quarter and full-year results, even as revenue shows modest growth. Henneman's purchase history shows he has been a consistent buyer on the open market in recent months, suggesting a sustained conviction despite the company's near-term profitability challenges. This is a director with direct board-level insight putting real money into the company during a period of weakness, which could signal either genuine confidence in a turnaround or simply routine portfolio maintenance by someone with deep knowledge of ongoing strategic efforts.
Director John Henneman purchases 5,000 shares of Anika Therapeutics amid revenue decline and ongoing losses.
John Henneman, a board member at Anika Therapeutics, purchased 5,000 shares at a time when the company is facing financial headwinds — revenue declined year-over-year and the company remains unprofitable with consecutive quarterly losses. The stock has recovered substantially from its lows and is now trading within reach of its recent highs, making this purchase notable because director buying typically signals conviction during weakness rather than after a significant rally. While the transaction size is modest relative to his holdings, the timing suggests either confidence that the turnaround is underway or simply a routine portfolio move that doesn't necessarily reflect a major conviction call. Investors should monitor whether this purchase signals Henneman's belief that the market has overshot the downside risk, or whether additional directors follow with similar buying patterns.
